The opinions are published by the European Commission in their original language. Only this version is the original one. If other linguistic versions appear on this page, these will be clearly identified. The opinions are those of the Scientific Committees. It does not necessarily reflect the position of the European Commission.
 
Opinion(76 KB) on the impact of arthropod borne diseases (including WNV) on the safety of blood used for transfusion as well as organs used for transplantation in the European Community. Adopted on16 October 2003

Opinion(271 KB) on the protection offered by natural rubber latex medical devices (medical gloves and condoms) against transmissible diseases”. Adopted on 16 october 2003
 
Opinion(117 KB) on revision of the scientific opinion on the effects of xylitol and other polyols on caries development adopted on 2 June 1999.  Adopted by The Scientific Committee on Medicinal Products and Medical Devices On 26 September 2002
 
Opinion(883 KB) on Medical Devices containing DEHP plasticised PVC; neonates and other groups possibly at risk from DEHP toxicity, adopted on 26 September 2002
 
Opinion(239 KB) on the safety of Human-Derived Products with regard TSE's adopted on 18 January 2002
 
Opinion(57 KB) on the State of the Art Concerning Xenotransplantation adopted on 1st October 2001
 
Opinion(60 KB) on the State of the Art Concerning Tissue Engineering adopted on 1st October 2001
 
Opinion(159 KB) on Natural rubber latex allergy adopted on 27 June 2000
 
Opinion(57 KB) on Toxicological Data on Colouring Agents for Medicinal Products: E 174 Silver adopted on 27 June 2000
 
Opinion(61 KB) on Quality and Safety of Blood adopted on 16 February 2000
 
Opinion(39 KB) on update of the opinion on the Risk Quantification for CJD Transmission via Substances of Human Origin, adopted on 16 February 2000
 
Opinion on the Use of Specified Risk Materials for the Manufacture of Implantable Medical Devices, adopted on 15 December 1999
 
Opinion on the Effects of Xylitol and Other Polyols on Caries Development, adopted on 2 June 1999
 
Opinion on Toxicological Data on Colouring Agents for Medicinal Products: Aluminium, adopted on 14 April 1999
 
Opinion on the Policy Regarding the Use of Blood and Blood Products adopted by Written Procedure on 24 March 1999
 
Opinion on the Safety of Hides and Skins, adopted on 24 March 1999
 
Opinion on Guidelines on the concept of «Clinical Superiority» regarding legislation on Orphan Medicinal Products adopted on 14 April 1999
 
Opinion on the safety of boric acid in medicinal products adopted on 10 February 1999
 
Opinion on the safety of benzyl alcohol in parenteral medicinal products, adopted on 10 February 1999
 
Opinion(156 KB) on the risk quantification for CJD transmission via substances of human origin, adopted on 21/10/98
 
Opinion on Toxicological data colouring agents for medicinal products : Canthaxanthine, adopted on 21 October 1998
 
Opinion on Toxicological Data on Colouring Agents for Medicinal Products: Amaranth, adopted on 21 October 1998
 
Opinion on Toxicological Data on Colouring Agents for Medicinal Products: Erythrosin, adopted on 21 October 1998
 
Opinion on guidelines on the concept of "similarity" regarding legislation on Orphan medicinal products, adopted on 21 October 1998
 
Opinion on starting materials used in human and veterinary medicinal products, for which there is a consumer health/safety concern that needs to be addressed by laying down and enforcing a GMP requirement, adopted on 21 October 1998
 
Opinion and report on the equivalency of alternative products to intestines of animal origin for use as surgical sutures, adopted on 16 September 1998